Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1980160 | 0.91 | CHRNA7 (0.57) | CHRNA7KCNH2CHRNB2CHRNA4HTR3A | |
| SCHEMBL1397905 | 0.84 | CHRNA7 (0.71) | CHRNA7KCNH2CHRNB2CHRNA4HTR3A | |
| SCHEMBL1449960 | 0.82 | CHRNA7 (0.71) | CHRNA7KCNH2CHRNB2CHRNA4HTR3A | |
| SCHEMBL930767 | 0.81 | CHRNA7 (0.77) | CHRNA7KCNH2CHRNB2CHRNA4HTR3A | |
| SCHEMBL18016323 | 0.80 | CHRNA7 (1.00) | CHRNA7KCNH2HTR3ACSNK1DMAPK11 | |
| SCHEMBL927767 | 0.80 | CHRNA7 (1.00) | CHRNA7KCNH2HTR3ACSNK1DMAPK11 | |
| SCHEMBL927821 | 0.78 | CHRNA7 (0.72) | CHRNA7KCNH2CHRNB2CHRNA4HTR3A | |
| SCHEMBL927820 | 0.78 | CHRNA7 (0.72) | CHRNA7KCNH2CHRNB2CHRNA4HTR3A | |
| SCHEMBL1740377 | 0.78 | CHRNA7 (0.61) | CHRNA7KCNH2CHRNB2CHRNA4HTR3A | |
| SCHEMBL2677127 | 0.77 | CHRNA7 (0.62) | CHRNA7CHRNB2CHRNA4HTR3ACHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110142758-A1 | INDOLYL-PYRIDAZINYL-DIAZABICYCLONONANE DERIVATIVES IN LABELLED AND UNLABELLED FORM AND THEIR USE IN DIAGNOSTIC METHODS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | claimed |
| US-20110142758-A1 | INDOLYL-PYRIDAZINYL-DIAZABICYCLONONANE DERIVATIVES IN LABELLED AND UNLABELLED FORM AND THEIR USE IN DIAGNOSTIC METHODS | NEUROSEARCH A/S (DK) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142758-A1 | INDOLYL-PYRIDAZINYL-DIAZABICYCLONONANE DERIVATIVES IN LABELLED AND UNLABELLED FORM AND THEIR USE IN DIAGNOSTIC METHODS | CNR2, CNR1, HTR3E | CHRNA7 102/4885KCNH2 598/4885CHRNB2 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.